WallStSmart
RLMD

Relmada Therapeutics Inc

NASDAQ: RLMD · HEALTHCARE · BIOTECHNOLOGY

$7.52
+2.04% today

Updated 2026-04-30

Market cap
$759.40M
P/E ratio
P/S ratio
9,001.90x
EPS (TTM)
$-1.45
Dividend yield
52W range
$0 – $8
Volume
2.1M

Relmada Therapeutics Inc (RLMD) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-23.9%
Last 4 quarters
Revenue YoY growth
Most recent quarter
EPS YoY growth
+53.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+7.3%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+13.7%
2026-03-24
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-24$-0.29-66.8%$5.86$6.66+13.7%
2025-11-13$-0.30+33.3%$3.91$3.95+1.0%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.17$-0.29-66.8%
2025-09-30$-0.45$-0.30+33.3%
2025-06-30$-0.40$-0.30+25.0%
2025-03-31$-0.31$-0.58-87.1%
2024-12-31$-0.70$-0.62+11.4%
2024-09-30$-0.64$-0.72-12.5%
2024-06-30$-0.83$-0.59+28.9%
2024-03-31$-0.85$-0.72+15.3%
2023-12-31$-0.83$-0.84-1.2%
2023-09-30$-0.91$-0.73+19.8%
2023-06-30$-0.90$-0.84+6.7%
2023-03-31$-0.89$-0.87+2.2%

Frequently asked questions

Has Relmada Therapeutics Inc beaten earnings estimates?
Relmada Therapeutics Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -23.9% over the last 4 quarters.
How does RLMD stock react to earnings?
RLMD stock has moved an average of +7.3% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.